A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

January 15, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

January 30, 2025

Conditions

Breast NeoplasmsNeoplasm Metastasis

Interventions

BIOLOGICAL

CodaLytic

CodaLytic is a virotherapeutic product based on the wild-type influenza strain A/California/07/2009

Trial Locations (2)

Gabrail Cancer Center, Canton

Dana Farber Cancer Institute, Boston